Search research articles
Contact Us
Filters
Showing results (61-70 of 252) with videos related to
Page
of 26
Sort By:
Expert Review of Anticancer Therapy
|
September 15, 2010
The role of PET in Hodgkin's lymphoma and its impact on radiation oncology
Carsten Kobe, Markus Dietlein, Jan Kriz, et al.
Hemasphere
|
June 23, 2022
Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD
Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, et al.
Nuclear Medicine Communications
|
November 22, 2018
Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction?
Conrad-Amadeus Voltin, Jasmin Mettler, Ronald Boellaard, et al.
Cancers
|
March 28, 2024
Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma-A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group
Michael Oertel, Priska Hölscher, Dominik Hering, et al.
Haematologica
|
August 5, 2018
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Haematologica
|
January 2, 2019
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Blood
|
May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis
Boris Böll, Hinrich Hansen, Friederike Heuck, et al.
Journal of Cancer Research and Clinical Oncology
|
July 6, 2025
Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma
Julia K Schleifenbaum, Jan-Michel Heger, Jonas Jost, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 15, 2026
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial
Fjoralba Kristo, Flora Mazerolle, Thibaud Alin, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group
Justin Ferdinandus, Lutz van Heek, Katrin Roth, et al.
Page
of 26
Search research articles
Search
Showing results (61-70 of 252) with videos related to
Sort By:
Page
of 26
Expert Review of Anticancer Therapy
|
September 15, 2010
The role of PET in Hodgkin's lymphoma and its impact on radiation oncology
Carsten Kobe, Markus Dietlein, Jan Kriz, et al.
Hemasphere
|
June 23, 2022
Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD
Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, et al.
Nuclear Medicine Communications
|
November 22, 2018
Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction?
Conrad-Amadeus Voltin, Jasmin Mettler, Ronald Boellaard, et al.
Cancers
|
March 28, 2024
Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma-A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group
Michael Oertel, Priska Hölscher, Dominik Hering, et al.
Haematologica
|
August 5, 2018
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Haematologica
|
January 2, 2019
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Blood
|
May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis
Boris Böll, Hinrich Hansen, Friederike Heuck, et al.
Journal of Cancer Research and Clinical Oncology
|
July 6, 2025
Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma
Julia K Schleifenbaum, Jan-Michel Heger, Jonas Jost, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 15, 2026
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial
Fjoralba Kristo, Flora Mazerolle, Thibaud Alin, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group
Justin Ferdinandus, Lutz van Heek, Katrin Roth, et al.
Page
of 26